XELOX和卡培他滨单药口服治疗结直肠癌患者的效果比较及护理  

Effect of the XELOX or capecitabine monotherapy on patients with colorectal cancer and nursing

作　　者：许珊珊[1] 王旭丹[1] 孙悦[1] 粱雪[1] 

机构地区：[1]哈尔滨医科大学附属二院结直肠肿瘤外科,150086

出　　处：《中华现代护理杂志》2013年第32期3985-3988,共4页Chinese Journal of Modern Nursing

摘　　要：目的：比较奥沙利铂＋卡培他滨（XELOX）和卡培他滨单药口服治疗结直肠癌（CRC）患者的效果，并探讨手足综合征（HFS）的发生率及护理方法。方法采用随机数字表法将80例CRC患者随机分为XELOX组50例和单药口服组30例，比较两组总生存率（OS）和HFS发生率。结果XELOX组和单药口服组中位生存时间分别为24．2个月和22．4个月，总生存率分别为78．0％，76．7％，差异无统计学意义（P＞0．05）；HFS 发生率分别为34．0％，60．0％，差异有统计学意义（χ2＝8．8，P ＝0．02）。结论XELOX和卡培他滨单药口服疗效无明显差别；XELOX可降低HFS发生率；对HFS的有效护理可保证卡培他滨长期用药。Objective To compare the effect between oxaliplatin plus capecitabine （XELOX） and capecitabine monotherapy in the treatment of colorectal cancer （CRC） in patients, and explore the incidence rate and nursing of hand -foot syndrome （HFS）.Methods Eighty patients with CRC were randomly divided into the XELOX group （n=50） and the monotherapy group （n=30） according to the random number table , and the overall survival （OS） and the incidence rate of HFS was compared between two groups .Results The median survival time were respectively 24.2 and 22.4 months in the XELOX and monotherapy group , and the overall survival rateswere respectively 78.0% and 76.7% in two groups, and the differences were not statistically significant （P〉0.05）.The incidence rates of HFS were respectively 34.0% and 60.0% in the XELOX and monotherapy group, and the difference was statistically significant （χ2 =8.8, P =0.02 ）.Conclusions The effect of the XELOX or capecitabine monotherapy on patients with colorectal cancer is no significant difference;XELOX can reduce the incidence rate of HFS;the effective nursing of HFS can ensure the long-term medication of capecitabine .

关 键 词：结直肠肿瘤 手足综合征 护理 卡培他滨 XELOX 

分 类 号：R473.73[医药卫生—护理学]